Publications by authors named "Patrick Derigs"
Article Synopsis
- Third-generation chimeric antigen receptor T cells (CARTs) may offer better treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) compared to second-generation CARTs due to improved design.
- In a phase 1/2 clinical trial with nine heavily pretreated patients, HD-CAR-1 targeting CD19 resulted in a significant response where 67% of patients achieved complete remission by day 90, with some showing undetectable minimal residual disease.
- The trial noted low toxicity, with only one case of severe cytokine release syndrome, while those who responded to treatment had a higher presence of CD4+ T cells compared to non-responders.
Article Synopsis
- The study focuses on patients with large B cell lymphoma (LBCL) who relapse after CAR-T therapy, highlighting that while outcomes are generally poor, some patients can achieve long-term survival.
- The German Lymphoma Alliance (GLA) suggests using allogeneic hematopoietic cell transplantation (alloHCT) as a potential treatment for those who experience CAR-T failure, with an emphasis on certain patient characteristics affecting outcomes.
- The analysis found that 18% of patients survived for over a year after relapse, and alloHCT was feasible and associated with a 36% overall survival rate at 12 months for those with sensitive or untreated relapses, suggesting it could be a viable option for eligible patients.
Background: Third-generation chimeric antigen receptor (CAR)-engineered T cells (CARTs) might improve clinical outcome of patients with B cell malignancies. This is the first report on a third-generation CART dose-escalating, phase-1/2 investigator-initiated trial treating adult patients with refractory and/or relapsed (r/r) acute lymphoblastic leukemia (ALL).
Methods: Thirteen patients were treated with escalating doses of CD19-directed CARTs between 1 × 10 and 50 × 10 CARTs/m.
Chimeric antigen receptor T (CAR-T) cell therapy has proven to be very effective in patients with relapsed/refractory acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL). However, infections-related either due to lymphodepletion or the CAR-T cell therapy itself-can result in severe and potentially life-threatening complications, while side effects such as cytokine release syndrome (CRS) might complicate differential diagnosis. Sixty-seven dosings of CAR-T cells in sixty adult patients with NHL (85%) and ALL (15%) receiving CAR-T cell therapy were assessed for infectious complications.
View Article and Find Full Text PDFMorbidity and mortality after allogeneic hematopoietic cell transplantation (alloHCT) are still essentially affected by reactivation of cytomegalovirus (CMV). We evaluated 80 seropositive patients transplanted consecutively between March 2018 and March 2019 who received letermovir (LET) prophylaxis from engraftment until day +100 and retrospectively compared them with 80 patients without LET allografted between January 2017 and March 2018. The primary endpoint of this study was the cumulative incidence (CI) of clinically significant CMV infection (CS-CMVi) defined as CMV reactivation demanding preemptive treatment or CMV disease.
View Article and Find Full Text PDFT lymphocytes against tumor-specific mutated neoantigens can induce tumor regression. Also, the size of the immunogenic cancer mutanome is supposed to correlate with the clinical efficacy of checkpoint inhibition. Herein, we studied the susceptibility of tumor cell lines from lymph node metastases occurring in a melanoma patient over several years towards blood-derived, neoantigen-specific CD8+ T cells.
View Article and Find Full Text PDF